. 2019 Dec 25;9(1):55. doi: 10.3390/jcm9010055

Table 5.

Acquired resistance to fluoroquinolone among initially susceptible cases ^#.

Setting, Core Drug	Initially Susceptible (A)	DST not Performed	Susceptible ^£	Acquired Resistance (B)	Acquired Resistance per 1000
Setting, Core Drug	Initially Susceptible (A)	DST not Performed	Susceptible ^£	Acquired Resistance (B)	(B/A)*1000
Bangladesh, Niger, Cameroon, GFX [23]	859	1	2	0	0
Bangladesh, Niger, Cameroon, LFX [23]	203	0	3	2	9.9
Bangladesh, Niger, Cameroon, MFX [23]	228	4	1	4	17.5
West/Central Africa ^$, MFX [12]	571	25	8	8	14.0
STREAM, MFX h [13]	246	NA	NA	5	20.3

NA: data not available. GFX: gatifloxacin; MFX: moxifloxacin; LFX: levofloxacin: the “h” after the name of the drug means high dosage. ^# Recurrence: either treatment failure or relapse. ^$ Benin, Burkina Faso, Burundi, Cameroon, CAR, Cote d’Ivoire, DRC, Rwanda, Niger. ^£ Patients who failed or relapsed with strains still susceptible to fluoroquinolone.